1. Home
  2. AGX vs DVAX Comparison

AGX vs DVAX Comparison

Compare AGX & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGX
  • DVAX
  • Stock Information
  • Founded
  • AGX 1961
  • DVAX 1996
  • Country
  • AGX United States
  • DVAX United States
  • Employees
  • AGX N/A
  • DVAX N/A
  • Industry
  • AGX Engineering & Construction
  • DVAX Biotechnology: Pharmaceutical Preparations
  • Sector
  • AGX Consumer Discretionary
  • DVAX Health Care
  • Exchange
  • AGX Nasdaq
  • DVAX Nasdaq
  • Market Cap
  • AGX 2.1B
  • DVAX 1.7B
  • IPO Year
  • AGX N/A
  • DVAX 2004
  • Fundamental
  • Price
  • AGX $185.46
  • DVAX $12.68
  • Analyst Decision
  • AGX Buy
  • DVAX Buy
  • Analyst Count
  • AGX 3
  • DVAX 2
  • Target Price
  • AGX $123.33
  • DVAX $23.00
  • AVG Volume (30 Days)
  • AGX 333.0K
  • DVAX 1.7M
  • Earning Date
  • AGX 12-05-2024
  • DVAX 02-20-2025
  • Dividend Yield
  • AGX 0.81%
  • DVAX N/A
  • EPS Growth
  • AGX 92.83
  • DVAX N/A
  • EPS
  • AGX 4.81
  • DVAX 0.15
  • Revenue
  • AGX $806,259,000.00
  • DVAX $260,810,000.00
  • Revenue This Year
  • AGX $47.84
  • DVAX $22.13
  • Revenue Next Year
  • AGX $6.90
  • DVAX $19.91
  • P/E Ratio
  • AGX $38.56
  • DVAX $83.61
  • Revenue Growth
  • AGX 52.83
  • DVAX N/A
  • 52 Week Low
  • AGX $43.44
  • DVAX $9.74
  • 52 Week High
  • AGX $185.01
  • DVAX $14.30
  • Technical
  • Relative Strength Index (RSI)
  • AGX 75.21
  • DVAX 50.85
  • Support Level
  • AGX $151.17
  • DVAX $12.21
  • Resistance Level
  • AGX $178.38
  • DVAX $12.74
  • Average True Range (ATR)
  • AGX 8.60
  • DVAX 0.36
  • MACD
  • AGX 3.77
  • DVAX -0.04
  • Stochastic Oscillator
  • AGX 99.48
  • DVAX 57.39

About AGX Argan Inc.

Argan Inc is a United States-base construction firm that conducts operations through its wholly-owned subsidiaries, GPS, APC, TRC and SMC. Through GPS and APC it provides a full range of engineering, procurement, construction, commissioning, maintenance, project development and technical consulting services to the power generation market, including the renewable energy sector, for a wide range of customers, including independent power project owners, public utilities, power plant heavy equipment suppliers and other commercial firms with power requirements in the U.S., Ireland and the U.K. It operates in three segments: Power Services, Industrial Services, and Telecom Services, out of which Power Services derive majority revenue.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: